Barbara Herfel, MD
Clinical Pathology · Lafayette, LANPI 1447425657
Payments from drug & device makers
Across 59 payments — averaging $1139.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$67K
- Biofire Diagnostics, LLC$23
- Novartis$22
- Eisai Inc.$18
- Merck$15
What the payments were for
- Consulting fees$66,86299%
- Travel & lodging$2970%
- Food & beverage$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 55 | $67,159 |
| Biofire Diagnostics, LLC | 1 | $23 |
| Novartis | 1 | $22 |
| Eisai Inc. | 1 | $18 |
| Merck | 1 | $15 |
How this compares
Too few clinical pathology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other clinical pathology in Lafayette
- Xiao-Ming YinNew Orleans$10K
- John ScottNew Orleans$114
- Betty ChungNew Orleans$70
- Estelle OertlingNew Orleans$20
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.